Management of HIV and hepatitis C virus infections in resource-limited settings

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 539-545

  Ocama, Ponsiano ^a   Seremba, Emmanuel ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b MULAGO HOSPITAL   (Uganda)

Author keywords

epidemiology; hepatitis C virus; HIV; resource limited setting; treatment

Indexed keywords

AFRICA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MIXED INFECTION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SCREENING TEST; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS TRANSMISSION;

AFRICA; ASIA; BLOOD TRANSFUSION; COINFECTION; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; EUROPE; HEALTH RESOURCES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE; SOUTH AMERICA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 80054938831     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bd23f     Document Type: Review

References (62)

1. Pawlotsky JM. HepatitisC virus: from discovery to eradication in 40 years. Clin Microbiol Infect 2011; 17:105-106.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-115.
3. Baldo v, Baldovin T, Trivello R, Floreani A. Epidemiology of HCv infection. Curr Pharm Des 2008; 14:1646-1654. (Pubitemid 351998588)
4. UNAIDS report on the Global AIDS epidemic, 2010.
5. Operskalski EA, Kovacs A. HIv/HCv co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIv/AIDS Rep 2011; 8:12-22.
6. Cavlek Tv, Marić J, Katicić L, Kolarić B. Hepatitis C virus antibody status, sociodemographic characteristics, and risk behaviour among injecting drug users in Croatia. Cent Eur J Public Health 2011; 19:26-29.
7. Gyarmathy vA, Li N, Tobin KE, et al. Correlates of unsafe equipment sharing among injecting drug users in St. Petersburg, Russia. Eur Addict Res 2009; 15:163-170.
8. Platt L, Sutton AJ, vickerman P, et al. Measuring risk of HIv and HCv among injecting drug users in the Russian Federation. Eur J Public Health 2009; 19:428-433.
9. Seme K, Lunar MM, Tomazic J, et al. Low prevalence of hepatitis B and C infections among HIv-infected individuals in Slovenia: a nation-wide study, 1986-2008. Acta Dermatovenerol Alp Panonica Adriat 2009; 18:153-156.
10. Shang H, Zhong P, Liu J, et al. High prevalence and genetic diversity of HCv among HIv-1 infected people from various high-risk groups in China. PLoS One 2010; 5:e10631.
11. Yang C, Latkin C, Luan R, et al. HIv, syphilis, hepatitis C and risk behaviours among commercial sex male clients in Sichuan province, China. Sex Transm Infect 2010; 86:559-564.
12. Yan YX, Gao YQ, Sun X, et al. Prevalence of hepatitis C virus and hepatitis B virus infections in HIv-positive Chinese patients. Epidemiol Infect 2011; 139:354-360.
13. Zhou S, Zhao Y, He Y, et al. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. J Acquir Immune Defic Syndr 2010; 54:191-196.
14. Bao YP, Liu ZM. Systematic review of HIv and HCv infection among drug users in China. Int J STD AIDS 2009; 20:399-405.
15. Laurent C, Bourgeois A,Mpoudi-NgoléE, et al. High rates of active hepatitis B and C co-infections in HIv-1 infected Cameroonian adults initiating antiretroviral therapy. HIv Med 2010; 11:85-89.
16. Mboto CI, Fielder M, Davies-Russell A, Jewell AP. Prevalence of HIv-1, HIv-2, hepatitis C and co-infection in The Gambia. West Afr J Med 2009; 28:16-19.
17. Mboto CI, Okonofua FE, Davies-Russell A, Jewell AP. Hepatitis C virus prevalence and serotypes associated with HIv in The Gambia. Br J Biomed Sci 2010; 67:140-144.
18. Jobarteh M, Okonofua FE, Peterson I, et al. Seroprevalence of hepatitis B and C virus in HIv-1 and HIv-2 infected Gambians. virol J 2010; 7:230.
19. Onakewhor JU, Okonofua FE. The prevalence of dual human immunodeficiency virus/hepatitis C virus (HIv/HCv) infection in asymptomatic pregnant women in Benin City, Nigeria. Afr J Reprod Health 2009; 13:97-108.
20. Akinbami AA, Oshinaike OO, Adeyemo TA, et al. Seroprevalence of hepatitis C infection in HIv patients using a rapid one-step test strip kit. Nig Q J Hosp Med 2010; 20:144-146.
21. Balogun TM, Emmanuel S, Wright KO. Hepatitis C virus co infection in HIv positive patients. Nig Q J Hosp Med 2010; 20:117-120.
22. Duru MU, Aluyi HS, Anukam KC. Rapid screening for co-infection of HIv and HCv in pregnant women in Benin City, Edo State, Nigeria. Afr Health Sci 2009; 9:137-142.
23. Adoga MP, Banwat EB, Forbi JC, et al. Human immunodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries 2009; 3:539-547.
24. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIv in sub- Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14:e1024-e1031.
25. Wester CW, Bussmann H, Moyo S, et al. Serological evidence of HIvassociated infection among HIv-1-infected adults in Botswana. Clin Infect Dis 2006; 43:1612-1615. (Pubitemid 44901905)
26. Kolarić B, Stajduhar D, Gajnik D, et al. Seroprevalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health 2010; 18:104-109.
27. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIv among people who inject drugs: a systematic review. Lancet 2008; 372:1733-1745.
28. Quan vM, Go vF, Nam le v, et al. Risks for HIv, HBv, and HCv infections among male injection drug users in northern vietnam: a case-control study. AIDS Care 2009; 21:7-16.
29. Tanimoto T, Nguyen HC, Ishizaki A, et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern vietnam. J Med virol 2010; 82:1355-1363.
30. Wu J, Huang J, Xu D, et al. Infection status and risk factors of HIv, HBv, HCv, and syphilis among drug users in Guangdong, China: a cross-sectional study. BMC Public Health 2010; 10:657.
31. Hosseini M, SeyedAlinaghi S, Kheirandish P, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010; 13:318-323.
32. van de Laar TJ, Matthews Gv, Prins M, Danta M. Acute hepatitis C in HIvinfected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24:1799-1812.
33. Ngo-Giang-Huong N, Jourdain G, Sirirungsi W, et al. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010; 14:e602-e607.
34. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, et al. HCv iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59:1554-1560.
35. Pepin J, Lavoie M, Pybus OG, et al. Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis 2010; 51:768-776.
36. Pepin J, Labbe AC, Mamadou-Yaya F, et al. Iatrogenic transmission of human T cell lymphotrophic virus type 1 and hepatitis C virus through parenteral treatment and chemoprophylaxis of sleeping sickness in colonial equatorial Africa. Clin Infect Dis 2010; 51:777-784.
37. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43:915-922. (Pubitemid 43724616)
38. Batina Agasa S, Dupont E, Kayembe T, et al. Multiple transfusions for sickle cell disease in the Democratic Republic of Congo: the importance of the hepatitis C virus. Transfus Clin Biol 2010; 17:254-259.
39. Buseri FI, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus 2009; 7:293-299.
40. Rouet F, Chaix ML, Inwoley A, et al. HBv and HCv prevalence and viraemia in HIv-positive and HIv-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med virol 2004; 74:34-40. (Pubitemid 38988857)
41. Seremba E, Ocama P, Opio CK, et al. Poor performance of hepatitis Cantibody tests in hospital patients in Uganda. J Med virol 2010; 82:1371-1378.
42. Benouda A, Boujdiya Z, Ahid S, et al. Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction. Pathol Biol (Paris) 2009; 57:368-372.
43. Kesli R, Ozdemir M, Kurtoglu MG, et al. Evaluation and comparison of three different antihepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res 2009; 37:1420-1429.
44. Ali A, Lal A. False positivity of serological tests for hepatitis C virus. J Ayub Med Coll Abbottabad 2010; 22:43-45.
45. Laperche S, Boukatou G, Kouegnigan L, et al. Transfusion safety on the African continent: an international quality control of virus testing in blood banks. Transfusion 2009; 49:1600-1608.
46. Boyer N, Marcellin P. Natural history of hepatitis C and the impact of antiviral therapy. Forum (Genova) 2000; 10:4-18. (Pubitemid 30160682)
47. Mallet v, vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011; 31 (Suppl 1):135-139.
48. John-Baptiste A, Krahn M, Heathcote J, et al. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010; 53:245-251.
49. Reiche EM, Bonametti AM, Morimoto HK, et al. Epidemiological, immunological and virological characteristics, and disease progression of HIv-1/HCvco- infected patients from a southern Brazilian population. Int JMol Med 2008; 21:387-395. (Pubitemid 351330491)
50. Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIv-infected patients. Clin Infect Dis 2009; 49:1274-1282.
51. Oyagbemi AA, Azeez OI, Saba AB. Hepatocellular carcinoma and the underlying mechanisms. Afr Health Sci 2010; 10:93-98.
52. Rodríguez-Torres M, Ríos-Bedoya CF, Rodríguez-Orengo J, et al. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus co-infection and along gender. J Clin Gastroenterol 2006; 40:358-366. (Pubitemid 44309530)
53. Mariné-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIv/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170. (Pubitemid 39463681)
54. Pineda JA, Macías J, Mira JA, et al. HAART and the liver: friend or foe? Eur J Med Res 2010; 15:93-96.
55. Aranzabal L, Casado JL, Moya J, et al. Influence of Liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIv and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-593. (Pubitemid 40270230)
56. Nunez M, Soriano v. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety 2005; 28:53-66.
57. Dore GJ, Torriani FJ, Rodriguez-Torres M, et al. Baseline factors prognostic of sustained virological response in patients with HIv-hepatitis C virus co-infection. AIDS 2007; 21:1555-1559. (Pubitemid 47075476)
58. Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCv treatment in HIv-infected persons. J viral Hepatol 2006; 13:683-689. (Pubitemid 44401197)
59. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIv/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47:36-49. (Pubitemid 351619367)
60. valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIv/hepatitis C viruscoinfected patients. J Acquir Immune Defic Syndr 2008; 47:50-55. (Pubitemid 351619368)
61. Carmo RA, Guimarães MD, Moura AS, et al. The influence of HCv coinfection on clinical, immunological and virological responses to HAART in HIv-patients. Braz J Infect Dis 2008; 12:173-179.
62. Bobrova N, Sarang A, Stuikyte R, Lezhentsev K. Obstacles in provision of antiretroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview. Int J Drug Policy 2007; 18:313-318. (Pubitemid 47135598)